Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 12

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 12
---
une 30, 2025 (#)

			Range of Exercise Prices 

			Expiry Dates

			37,719

			37,719

			C$
			15.12

			 August 2027 - Dec 2028

			43,031

			43,031

			$
			22.12

			Feb 2030

			51,006

			51,006

			$
			52.08 - 56.49

			September 2030 - Oct 2030

			79,651

			79,651

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			56,865

			56,865

			$
			25.97

			March 2025 - Feb 2032

			109,963

			84,346

			$
			4.10 - 10.01

			March 2025 - Oct 2033

			378,235

			352,618

The options exercisable at June 30, 2025 had a weighted average exercise price of $25.93, no intrinsic value and a weighted average remaining life of 72 months. There were 25,617 options at June 30, 2025 that had not vested with a weighted average exercise price of $7.00, no intrinsic value and a weighted average remaining life of 95 months.

The fair value of options granted during the nine months ended June 30, 2025 and 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Nine Months Ended June 30, 2024

			Risk free interest rate

			4.92
			%

			Expected life

			5 years

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

As of June 30, 2025, the Company had approximately $0.01 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 15 months.

Restricted share units (RSU)

The Company’s 2019 Plan allows restricted share units (RSUs) to be granted to directors, officers, employees and certain external consultants and advisers.